First Citizens Bank & Trust Co. Purchases 11,577 Shares of Eli Lilly And Co (LLY)

First Citizens Bank & Trust Co. boosted its position in Eli Lilly And Co (NYSE:LLY) by 334.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 15,042 shares of the company’s stock after purchasing an additional 11,577 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Eli Lilly And Co were worth $1,614,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in LLY. Integrated Wealth Concepts LLC bought a new position in Eli Lilly And Co in the second quarter worth about $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Eli Lilly And Co in the second quarter worth about $114,000. Legacy Advisors LLC raised its holdings in Eli Lilly And Co by 118.0% in the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after purchasing an additional 733 shares in the last quarter. Fort L.P. bought a new position in Eli Lilly And Co in the second quarter worth about $121,000. Finally, Financial Management Professionals Inc. bought a new position in Eli Lilly And Co in the second quarter worth about $128,000. Institutional investors and hedge funds own 76.38% of the company’s stock.

A number of equities analysts have commented on the stock. DZ Bank reiterated a “hold” rating on shares of Eli Lilly And Co in a report on Friday, June 22nd. Barclays boosted their price target on Eli Lilly And Co from $112.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, October 12th. Cantor Fitzgerald set a $100.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a research note on Tuesday, July 24th. ValuEngine upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Monday, October 8th. Finally, Credit Suisse Group set a $84.00 price target on Eli Lilly And Co and gave the stock a “hold” rating in a research note on Friday, July 13th. One analyst has rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $109.80.

In related news, SVP Alfonso G. Zulueta sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, October 4th. The stock was sold at an average price of $114.64, for a total value of $802,480.00. Following the sale, the senior vice president now owns 45,224 shares in the company, valued at $5,184,479.36. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 185,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 24th. The shares were sold at an average price of $92.03, for a total value of $17,025,550.00. Following the completion of the sale, the insider now owns 121,631,601 shares in the company, valued at approximately $11,193,756,240.03. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,960,271 shares of company stock worth $199,950,452. 0.11% of the stock is owned by insiders.

Shares of LLY stock opened at $113.31 on Friday. Eli Lilly And Co has a fifty-two week low of $73.69 and a fifty-two week high of $116.61. The stock has a market cap of $121.99 billion, a PE ratio of 22.58, a price-to-earnings-growth ratio of 1.84 and a beta of 0.29. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The business had revenue of $6.36 billion for the quarter, compared to analyst estimates of $6.05 billion. During the same quarter in the previous year, the firm earned $1.11 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. Sell-side analysts predict that Eli Lilly And Co will post 5.47 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be given a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a yield of 1.99%. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: What is a stock split?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply